Plain-English translation of NCT06523608 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing whether two risk prediction tools—called PLEASE and M10S20—can help doctors personalize monitoring schedules for people with advanced chronic liver disease. Instead of following the same check-up schedule for everyone, this approach categorizes patients as higher or lower risk, which may lead to more frequent or less frequent appointments depending on individual risk. The goal is to catch serious liver complications like liver cancer earlier.
People with advanced liver disease face serious risks, including liver cancer and sudden organ failure, but not everyone needs the same monitoring frequency. This study exists to see whether using personalized risk scores to guide when and how often patients are monitored can improve outcomes and catch dangerous changes sooner.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either standard monitoring (checkups every 6 months or more often if needed) or personalized risk-based monitoring. If you are assigned to the personalized group, the study will calculate your risk score and schedule you accordingly—either within 3 months if you're higher risk, or in one year if you're lower risk. At each visit, you'll have an ultrasound, blood tests, and sometimes CT or MRI scans, along with standard liver disease care provided by your medical team.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Germany